<SEC-DOCUMENT>0001558370-21-015611.txt : 20211112
<SEC-HEADER>0001558370-21-015611.hdr.sgml : 20211112
<ACCEPTANCE-DATETIME>20211112063021
ACCESSION NUMBER:		0001558370-21-015611
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211111
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211112
DATE AS OF CHANGE:		20211112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		211399258

	BUSINESS ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>adap-20211111x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/12/2021 10:52:33 AM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: c87317f7-1754-4eab-a264-b6e3bdcdee7d -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:adap="http://www.adaptimmune.com/20211111" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:EntityCentralIndexKey" id="Tc_K0B6GCKhXk64tMVNYj4Jhw_2_1">0001621227</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:AmendmentFlag" id="Tc_Yd_Lzulitk6LloHAgbjwsw_3_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:EntityTaxIdentificationNumber" id="Hidden_b4_yFgdqWkOwJ-IYmkxJwQ">00-0000000</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="adap-20211111.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001621227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-11</xbrli:startDate><xbrli:endDate>2021-11-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_e67b434a_9646_4165_9145_4cadc950e77c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES <br />SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:DocumentType" id="Narr_VdhGFFm8-Ei3Rica3e48EA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Current Report</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported):<b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_eivrLG6l10yYaN89xFQNlA"><b style="font-weight:bold;">November 11, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:EntityRegistrantName" id="Narr_q_BDZTPzO0uZqD8oR5dgFQ"><b style="font-weight:bold;">ADAPTIMMUNE THERAPEUTICS PLC</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_63905b76_9f4a_49a5_89e5_a7c5961bc63b"></a><a id="Tc_1AcFsc43yUu-1923140q6Q_2_0"></a><a id="Tc_j87BRx7yt0eOwPzOgb8a0w_2_2"></a><a id="Tc_P9d3SSoiZEaA8Ul3STK05w_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="Tc_Mu2UvJfHkUa24iLWOsiiNw_1_0"><b style="font-weight:bold;">England and Wales</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:EntityFileNumber" id="Tc_wyW93kJk_UCOqtXp-JxLoA_1_2"><b style="font-weight:bold;">1-37368</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_b4_yFgdqWkOwJ-IYmkxJwQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">Not Applicable</b></span></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction of<br />incorporation)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:EntityAddressAddressLine1" id="Narr_jp_Tq76IXUupZvNCH-rRqA"><b style="font-weight:bold;">60 Jubilee Avenue</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:EntityAddressAddressLine2" id="Narr_bwH99eBBdkS5zCPeRI6pLw"><b style="font-weight:bold;">Milton Park</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:EntityAddressCityOrTown" id="Narr_K5eVgxipxUSZAFVEARiq_w"><b style="font-weight:bold;">Abingdon, Oxfordshire</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:EntityAddressPostalZipCode" id="Narr_k0xbhFQvBEWhNGI-YBwYiQ"><b style="font-weight:bold;">OX14 4RX</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="Narr_cHiXPKlpMUC7-oTQPTcb3g"><b style="font-weight:bold;">United Kingdom</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of principal executive offices, including zip code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:CityAreaCode" id="Narr_SyJwFvkxWUu7B4_YBM8aRA"><b style="font-weight:bold;">44</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:LocalPhoneNumber" id="Narr_kTqH1MbsXU-qdIMdXaHAdw"><b style="font-weight:bold;">1235 430000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_OHfC4Yq-k0mjtq_C93airw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_m1AR_1wvukON3-YSbXAo2g"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_uBO81eqNaE-G6Wlz5fXuuw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_bCNFmsAdOUaYaEkX0zLVJA"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_602dac61_edc2_4936_8590_9ecf753fb00c"></a><a id="Tc_Unk7N3rcKkeI7_oHVJPiyA_0_0"></a><a id="Tc_bUjiSeeAW0iEBrL8k5RH1g_0_2"></a><a id="Tc_prWr9ug6G0mrahUEUjvc1g_0_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading&#160;Symbol</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which<br />registered</b></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:Security12bTitle" id="Tc_aW8GY_i3p0O_q7nxwaq1-w_1_0">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" name="dei:TradingSymbol" id="Tc_l0Arp2Wq2E636JbM7a-8OA_1_2">ADAP</ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_scFZmn_VwUm2pkByXq821Q_1_4">The Nasdaq Global Select Market</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 18pt 0pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_xZ9EDTVAJUChZpNlz46L9A"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 7.01&#160;&#160;&#160;&#160;Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November 11, 2021, Adaptimmune Therapeutics plc (&#8220;Adaptimmune&#8221;) issued a press release announcing updated clinical and translational data from its pivotal SPEARHEAD-1 trial with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) to be presented at the Connective Tissue Oncology Society (CTOS) annual meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Clinical data will be presented in an oral presentation by Dr. Brian Van Tine of the Washington University School of Medicine in St. Louis (Abstract #1080870) during the Immunotherapy &amp; Immune Microenvironment Session starting at 10:00 a.m. EST on November 12, 2021. Preliminary translational insights from the Phase 2 SPEARHEAD-1 trial will also be presented in a poster (Abstract #1080366) by Dr. Sandra P. D&#8217;Angelo of Memorial Sloan Kettering Cancer Center during the Immunology &amp; Immunotherapy Session beginning at 2:30 p.m. EST on November 12, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The press release is furnished as Exhibit 99.1 and is incorporated by reference herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information in this Item 7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">(d)&#160; Exhibits.</p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:86%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Exhibit</b></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><a style="-sec-extract:exhibit;" href="adap-20211111xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.37;text-align:left;">Press release dated November 11, 2021</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Cover Page Interactive Date File (embedded within the Inline XBRL document)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">ADAPTIMMUNE THERAPEUTICS PLC</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Date: November 12, 2021</p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">/s/ Margaret Henry</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Margaret Henry</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>adap-20211111xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 10:52:46 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;text-align:right;margin:0pt 0pt 6pt 0pt;">Exhibit 99.1</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><img src="adap-20211111xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:43.93pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:226.48pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="background-color:#ffffff;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="background-color:#ffffff;">- </font>SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year<font style="background-color:#ffffff;"> -</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="background-color:#ffffff;">- The overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with MRCLS) and the disease control rate was 85% -</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="background-color:#ffffff;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="background-color:#ffffff;">- As of the data cut-off, afami-cel has shown a favorable benefit:risk profile -</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="background-color:#ffffff;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="background-color:#ffffff;">- </font>Translational data confirm that afami-cel is active against MAGE-A4 expressing targets both <i style="font-style:italic;">in vitro</i> and</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"> <i style="font-style:italic;">in vivo</i>, and maintained high levels of persistence in the majority of patients followed for at least </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;">6 months post-infusion -</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="background-color:#ffffff;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="background-color:#ffffff;">PHILADELPHIA, PA., and OXFORDSHIRE, U.K.,&#160;Nov. 11&#160;(GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report updated clinical and translational data from its pivotal SPEARHEAD-1 trial with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) at the&#160;Connective Tissue Oncology Society&#160;(CTOS) annual meeting.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="background-color:#ffffff;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="background-color:#ffffff;">&#8220;The positive results presented at CTOS further validate the potential of this therapy to address a great unmet medical need for patients with synovial sarcoma and MRCLS,&#8221; said Elliot Norry, Adaptimmune&#8217;s Chief Medical Officer. &#8220;We are confident that these data will support our BLA filing for afami-cel next year.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="background-color:#ffffff;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="background-color:#ffffff;">&#8220;Afami-cel would provide a new treatment option for patients with synovial sarcoma, offering benefits that we have rarely seen with therapies currently available for this patient population,&#8221; said Dr. Brian A. Van Tine, Professor of Medicine and of Pediatrics at Washington University School of Medicine in St. Louis. &#8220;This is a game changer for patients with a high unmet medical need.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="background-color:#ffffff;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="background-color:#ffffff;">Clinical data will be presented in an oral presentation by Dr. Brian Van Tine of the Washington University School of Medicine in St. Louis (Abstract #1080870) during the Immunotherapy &amp; Immune Microenvironment Session starting at 10:00 a.m. EST on November 12</font><sup style="background-color:#ffffff;font-size:8.25pt;vertical-align:top;">th</sup><font style="background-color:#ffffff;">. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="background-color:#ffffff;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="background-color:#ffffff;">Preliminary translational insights from the Phase 2 SPEARHEAD-1 trial will also be presented in a poster (Abstract #1080366) by Dr. Sandra P. D&#8217;Angelo of Memorial Sloan Kettering Cancer Center during the Immunology &amp; Immunotherapy Session beginning at 2:30 p.m. EST on November 12</font><sup style="background-color:#ffffff;font-size:8.25pt;vertical-align:top;">th</sup><font style="background-color:#ffffff;">. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="background-color:#ffffff;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="background-color:#ffffff;font-weight:bold;">Efficacy data validate the meaningful clinical benefit of afami-cel (data cut-off September 1, 2021)</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">50 patients had received afami-cel (42 with synovial sarcoma, 8 with MRCLS)</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Median age of patients was 41 years (range: 19 to 73) and they had received a median of three prior lines of therapy (range: 1 to 12)</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">The median dose was 8.5 billion transduced SPEAR T-cells (range: 2.7 to 10)</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Three patients had scans awaiting Independent Review and 47 patients were evaluable </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">The primary endpoint for SPEARHEAD-1 is response according to RECIST v1.1 evaluated by Independent Review </font><sup style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;text-align:left;vertical-align:top;"><a style="line-height:1.27;margin-bottom:0pt;margin-top:0pt;vertical-align:super;" href="#footnote-2">1</a></sup></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Based on the reported overall response rate, the trial will meet its primary endpoint in the final analysis planned later this year</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Per Independent Review, the overall response rate was 34% (16/47 patients with partial responses [PRs]) </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">The overall response rate was 36% in patients with synovial sarcoma, and 25% for patients with MRCLS</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.37;text-align:left;">The disease control rate (defined as stable disease, PR, or CR) was 85% per Independent Review</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">The overall response rate and disease control rate per Independent Review were comparable to the assessments by Investigator Review (34% and 84%, respectively) </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Durability is encouraging and the median duration of response has not been reached</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">75% of patients with response remain ongoing and the duration ranged from 4.3</font><sup style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;text-align:left;vertical-align:top;">+</sup><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> to 65.3</font><sup style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;text-align:left;vertical-align:top;">+</sup><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> weeks</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="background-color:#ffffff;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="background-color:#ffffff;font-weight:bold;">Afami-cel was well-tolerated and has a favorable benefit:risk profile as of data cut-off</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Thirty-three (66%) patients experienced adverse events of cytokine release syndrome (CRS), most of which were lower grade: Grade 1 or 2 (n=32); Grade 3 (n=1)</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">The most common serious adverse event (SAE) of any grade was CRS reported in 6% of patients</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Eight (16%) patients experienced &#8805; Grade 3 cytopenia at Week 4</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Emerging translational data support clinical benefit seen in patients with afami-cel</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Afami-cel SPEAR T-cells successfully engrafted in all patients and maintained high levels of persistence in most patients followed for at least 6 months post-infusion </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">CD8+ SPEAR T-cells in drug products administered killed &gt;70% tumor cells </font><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:left;">in vitro</i><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Serum cytokine response profile indicates an IFN&#947;-driven mechanism of action, signaling an afami-cel induced immune response </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Clinical benefit seen across a broad range of MAGE-A4 expression </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Post-infusion biopsies indicated that infiltrating afami-cel SPEAR T-cells co-localize with tumor and additional immune cells, with evidence of activated and proliferative state and adaptive-immune response</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Conclusion from the Phase 2 SPEARHEAD-1 trial</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">The trial will meet its primary endpoint for efficacy for this pivotal trial </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">As of September 1, 2021, overall response rate was 34% with a disease control rate of </font><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">85% per Independent Review in 47 </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">heavily pre-treated </font><font style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">patients</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Durability of responses is encouraging, and the median duration of response has not been reached </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">The benefit:risk profile of afami-cel has been favorable, with mainly low-grade CRS and tolerable/reversible hematologic toxicities</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Translational data confirm that afami-cel is active against MAGE-A4 expressing targets both in vitro and in vivo</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">These data will be used to support Adaptimmune&#8217;s Biologics License Application (BLA) submission next year</font></td></tr></table><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Overview of SPEARHEAD-1 trial design</b><br>SPEARHEAD-1 is a Phase 2, open-label trial for people with advanced synovial sarcoma or MRCLS to evaluate the efficacy, safety, and tolerability of afami-cel. Afami-cel SPEAR T-cells target MAGE-A4<sup style="font-size:8.25pt;vertical-align:top;">+</sup>&#160;tumors. MAGE-A4 is </p><div style="margin-bottom:5pt;margin-top:15pt;width:25%;border-bottom:1px solid black;"></div><a name="footnote-2"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">1</sup> The primary endpoint will be evaluated using a one-sided exact-based Clopper-Pearson 97.5% confidence interval (CI). If the lower bound of the CI exceeds the response rate reported with historical second line therapy(ies) (18%), the trial will have met the pre-specified threshold for demonstrating efficacy.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">highly expressed in synovial sarcoma and MRCLS in the context of HLA-A*02. Compelling clinical responses in patients with synovial sarcoma were previously reported with afami-cel in a Phase 1 trial (CTOS 2020).</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">Approximately 90 patients are planned to be treated: 45 in Cohort 1 and 45 in Cohort 2. Enrollment in Cohort 1 is complete, and Cohort 2 is currently recruiting. The primary efficacy analysis will be for Cohort 1 only, which will be used to support the BLA filing next year. No formal hypothesis testing is planned for Cohort 2. Cohort 2 will strengthen the efficacy and safety database and will aid in descriptive sub-group analyses.</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">Key eligibility criteria: ECOG performance status of 0 or 1; HLA*02 positive with MAGE-A4 expression in &#8805; 30% of tumor cells &#8805; 2<sup style="font-size:8.25pt;vertical-align:top;">+</sup>&#160;by immunohistochemistry; aged &#8805; 16 and &#8804;&#160;75 years; and patients must have received either an anthracycline- or ifosfamide-containing regimen. Eligible patients received afami-cel doses between 1&#8211;10 &#215; 10<sup style="font-size:8.25pt;vertical-align:top;">9</sup>&#160;transduced T-cells after receiving lymphodepleting chemotherapy.</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">About Adaptimmune</b>&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company&#8217;s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b>&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">This release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our&#160;Quarterly Report on Form 10-Q&#160;filed with the Securities and Exchange Commission (SEC) on&#160;November 4,&#160;2021,&#160;and our other SEC filings.&#160;The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Adaptimmune Contacts:</b>&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Media Relations:</b>&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">S&#233;bastien Desprez &#8212; VP,&#160;Corporate Affairs and Communications&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">T: +44 1235 430 583&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">M: +44 7718 453 176&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><u style="text-decoration:underline;">Sebastien.Desprez@adaptimmune.com</u>&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Investor Relations:</b>&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">Juli P. Miller, Ph.D. &#8212;&#160;VP, Investor Relations&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">T: +1 215 825 9310&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">M: +1 215 460 8920&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><u style="text-decoration:underline;">Juli.Miller@adaptimmune.com</u>&#160;</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>adap-20211111xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adap-20211111xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !) 4L# 2(  A$! Q$!_\0
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MUK0]7TVWN=.U-&U"SE#Q;-P)!(SCCJ, _A78CP=X=  _LBU_[YI?^$/\._\
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M[7_T!Z<&_K7S8/\ AE3Q[;IJ&K^%;>?)2XEV28XR&:,'^=>AHBQHJ(H55&
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M(!)_$DUQWQ5B$5KI=_'A;B*8JK@<],C\B*[C2?\ D#6/_7O'_P"@BN+^+/\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>adap-20211111.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 10:52:37 AM-->
<!--Modified on: 11/12/2021 10:52:37 AM-->
<xsd:schema xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:attributeFormDefault="unqualified" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2021" targetNamespace="http://www.adaptimmune.com/20211111" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:adap="http://www.adaptimmune.com/20211111" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="adap-20211111_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adap-20211111_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="adap_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>adap-20211111_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 10:52:37 AM-->
<!--Modified on: 11/12/2021 10:52:37 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="adap-20211111.xsd#adap_DocumentAndEntityInformationAbstract" xlink:label="adap_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="adap_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adap_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>adap-20211111_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 10:52:37 AM-->
<!--Modified on: 11/12/2021 10:52:37 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="adap-20211111.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adap-20211111.xsd#adap_DocumentAndEntityInformationAbstract" xlink:label="adap_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637723111572598369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637723111572598369" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637723111572598369" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637723111572598369" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637723111572598369" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637723111572598369" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637723111572598369" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_637723111572598369" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637723111572598369" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637723111572598369" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCountry_637723111572598369" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637723111572598369" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637723111572598369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637723111572598369" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637723111572608376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637723111572608376" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637723111572608376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637723111572608376" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637723111572608376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637723111572608376" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637723111572608376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637723111572608376" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637723111572608376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637723111572608376" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637723111572608376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637723111572608376" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637723111572608376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637723111572608376" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637723111572608376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637723111572608376" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637723111572608376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637723111572608376" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637723111572608376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637723111572608376" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>adap-20211111x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adap-20211111.xsd" xlink:type="simple"/>
    <context id="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001621227</identifier>
        </entity>
        <period>
            <startDate>2021-11-11</startDate>
            <endDate>2021-11-11</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Tc_K0B6GCKhXk64tMVNYj4Jhw_2_1">0001621227</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Tc_Yd_Lzulitk6LloHAgbjwsw_3_1">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Hidden_b4_yFgdqWkOwJ-IYmkxJwQ">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:DocumentType
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_VdhGFFm8-Ei3Rica3e48EA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_eivrLG6l10yYaN89xFQNlA">2021-11-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_q_BDZTPzO0uZqD8oR5dgFQ">ADAPTIMMUNE THERAPEUTICS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Tc_Mu2UvJfHkUa24iLWOsiiNw_1_0">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Tc_wyW93kJk_UCOqtXp-JxLoA_1_2">1-37368</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_jp_Tq76IXUupZvNCH-rRqA">60 Jubilee Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_bwH99eBBdkS5zCPeRI6pLw">Milton Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_K5eVgxipxUSZAFVEARiq_w">Abingdon, Oxfordshire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_k0xbhFQvBEWhNGI-YBwYiQ">OX14 4RX</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_cHiXPKlpMUC7-oTQPTcb3g">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_SyJwFvkxWUu7B4_YBM8aRA">44</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_kTqH1MbsXU-qdIMdXaHAdw">1235 430000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_OHfC4Yq-k0mjtq_C93airw">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_m1AR_1wvukON3-YSbXAo2g">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_uBO81eqNaE-G6Wlz5fXuuw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_bCNFmsAdOUaYaEkX0zLVJA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Tc_aW8GY_i3p0O_q7nxwaq1-w_1_0">American Depositary Shares, each representing 6 Ordinary Shares, par value &#xa3;0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Tc_l0Arp2Wq2E636JbM7a-8OA_1_2">ADAP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Tc_scFZmn_VwUm2pkByXq821Q_1_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA"
      id="Narr_xZ9EDTVAJUChZpNlz46L9A">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140177161041496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adap_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 11,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-37368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADAPTIMMUNE THERAPEUTICS PLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">60 Jubilee Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Milton Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Abingdon, Oxfordshire<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX14 4RX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1235 430000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001621227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adap_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adap_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M>FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " #),VQ3F5R<(Q &  "<)P  $P
M            @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M ,DS;%-AMR/M@ 0  $H1   8              " @0P(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " #),VQ3GZ ;\+$"  #B#   #0
M            @ '"#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,DS;%.7
MBKL<P    !,"   +              "  9X/  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( ,DS;%,<.&7J/P$  #P"   /              "  8<0  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #),VQ3)!Z;HJT   #X 0  &@
M        @ 'S$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #),VQ399!YDAD!  #/ P  $P              @ '8$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   B%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="adap-20211111x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="adap-20211111x8k.htm">adap-20211111x8k.htm</File>
    <File>adap-20211111.xsd</File>
    <File>adap-20211111_lab.xml</File>
    <File>adap-20211111_pre.xml</File>
    <File>adap-20211111xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "adap-20211111x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "adap-20211111x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adap-20211111_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adap-20211111_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "adap-20211111.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "adap",
   "nsuri": "http://www.adaptimmune.com/20211111",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adap-20211111x8k.htm",
      "contextRef": "Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adap-20211111x8k.htm",
      "contextRef": "Duration_11_11_2021_To_11_11_2021_dUWGbZgVhUqS7N2NT3LHxA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "adap_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.adaptimmune.com/20211111",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-21-015611-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-015611-xbrl.zip
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MUB&YO)[1,KA3S&5RG8R2RW:*2B;;R1C8-(I9F>3S!M=K_%AL</!*V*(]NV2
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M/5W69#W_:H)_?7Q8+)+=77/0S/ZNG)-&+>>>C-?P?THM'S!]CMG@92/FSRG
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M_O"V!.CC'NT57;H-=5&%__E<W"",.JXX%#X:+?RNE.QC@GCK^OCW3A"*G/G
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MR,$#"]1Z,C1B68 VL:Y;G4B34LSR-"3S-@!5".8DLO+P+NDO5>5T@ZI<J&1
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M#3>H@&>QT.0PV9 :H#C0?.?X"QV%O7NPO] F*_7OY;.'Y\$%5@;*>DBTR8-
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MG%-((-S8U(*RRR).9R+F&>;0E '<<",#,'1%Q9DK=&\-W5NL6E+L0!'<EZ5
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M,#(Q,3$Q,5]P<F4N>&UL4$L! A0#%     @ R3-L4ZE5XR_A%   ,(\  !0
M             ( !B X  &%D87 M,C R,3$Q,3%X.&LN:'1M4$L! A0#%
M  @ R3-L4ZBV_W:H%0  U)$  !@              ( !FR,  &%D87 M,C R
F,3$Q,3%X97@Y.60Q+FAT;5!+!08     !0 % $T!  !Y.0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
